Thinking through this, @Relax1, DuPont’s acquisition of Oxymem doesn’t help Oxymem in China. DuPont’s American. Whatever little presence Oxymem has in China is going to be made harder for Oxymem to surmount, accepted, validated etc. Doesn’t pay to be American to do biz in China at the moment but great for companies with Israeli credentials and ownership.
Are we going to see a two tier market evolving? Oxy in the US and Europe, and SUBRE and Aspiral for China going forward? We shall see.
Add to My Watchlist
What is My Watchlist?
